The Rising Potential for the Newest and Most Promising of Cancer Treatments
NEEDHAM, MA--(Marketwired - June 07, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, provides the life science sciences community the Cancer Immunotherapy Report, a report focusing the three principal types of therapeutics that have become the major focuses of research and development in cancer immunotherapy; Checkpoint inhibitors, Therapeutic anticancer vaccines and Adoptive cellular immunotherapy.
The Cancer Immunotherapy Report also includes a survey on adoptive immunotherapy for cancer and three expert interviews with three high-end professors, researchers and CEOs:
For more information on these reports visit: InsightPharmaReports.com/Cancer-Immunotherapy-Report
About Insight Pharma Reports (www.insightpharmareports.com)
Insight Pharma Reports, a division of Healthtech Publishing, is the premier life sciences information provider offering unparalleled coverage of key issues in drug discovery and development. The reports are used by leading pharmaceutical, biotech, diagnostic, and other life science companies to keep abreast of the latest developments in pharmaceutical R&D and their potential applications and business impacts. The reports are written by experts in consulting and industry, and are supported by hundreds of hours of primary and secondary research. Insight Pharma Reports provide comprehensive coverage of salient issues in a concise, well-organized format.
About Healthtech Publishing
(www.healthtechpublishing.com)
Healthtech Publishing, a division of Cambridge Healthtech Institute, provides the life science communities with business critical intelligence through research reports and digital news, helping decision makers to gain competitive advantage and make strategic decisions. Our portfolio consists of Insight Pharma Reports' vast research reports collection and three niche digital subscription products: Bio-IT World, Clinical Informatics News and Diagnostics World.
Contact Information:
For more information:
Daniel Miller
Insight Pharma Reports
dmiller@insightpharmareports.com